| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1034862845 |
| P356 | DOI | 10.1186/AR2325 |
| P932 | PMC publication ID | 2246236 |
| P698 | PubMed publication ID | 17996099 |
| P5875 | ResearchGate publication ID | 5850986 |
| P50 | author | Jean-Pierre Pelletier | Q1266067 |
| Johanne Martel-Pelletier | Q1697061 | ||
| Daniel Lajeunesse | Q88426712 | ||
| Hassan Fahmi | Q89553792 | ||
| Steeve Kwan Tat | Q114415033 | ||
| Eulàlia Montell | Q114415034 | ||
| P2093 | author name string | Martin Lavigne | |
| Josep Vergés | |||
| P2860 | cites work | Osteoprotegerin expression and secretion are regulated by calcium influx through the L-type voltage-sensitive calcium channel | Q28206882 |
| Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis | Q28374250 | ||
| Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis | Q33993736 | ||
| Transcriptional induction of the osteocalcin gene during osteoblast differentiation involves acetylation of histones h3 and h4. | Q34173466 | ||
| Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis | Q34214244 | ||
| N-acetylglucosamine prevents IL-1 beta-mediated activation of human chondrocytes | Q34514554 | ||
| Glucosamine modulates IL-1-induced activation of rat chondrocytes at a receptor level, and by inhibiting the NF-kappa B pathway | Q34520479 | ||
| Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritis articular chondrocytes | Q34534426 | ||
| Naturocetic (glucosamine and chondroitin sulfate) compounds as structure-modifying drugs in the treatment of osteoarthritis | Q34536828 | ||
| Differential roles for small leucine-rich proteoglycans in bone formation. | Q35561073 | ||
| Recent advances in glucosamine and chondroitin supplementation | Q35955977 | ||
| RANK, RANKL and osteoprotegerin in arthritic bone loss | Q36078073 | ||
| The efficacy of glucosamine and chondroitin sulfate in the treatment of osteoarthritis: are these saccharides drugs or nutraceuticals? | Q36260594 | ||
| Can altered production of interleukin-1beta, interleukin-6, transforming growth factor-beta and prostaglandin E(2) by isolated human subchondral osteoblasts identify two subgroups of osteoarthritic patients | Q38288322 | ||
| Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. | Q38296222 | ||
| Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. | Q38311660 | ||
| Modulation of insulin-like growth factor 1 levels in human osteoarthritic subchondral bone osteoblasts | Q38319364 | ||
| Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells | Q38336153 | ||
| Human adult chondrocytes express hepatocyte growth factor (HGF) isoforms but not HgF: potential implication of osteoblasts on the presence of HGF in cartilage | Q38353421 | ||
| Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association | Q39513001 | ||
| The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells | Q39970700 | ||
| OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation | Q40271933 | ||
| Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium. | Q40486045 | ||
| Transforming growth factor-beta induces osteoclast formation in the absence of RANKL. | Q40594156 | ||
| TGF-beta enhances osteoclast differentiation in hematopoietic cell cultures stimulated with RANKL and M-CSF. | Q40919705 | ||
| Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines | Q41000781 | ||
| Osteoprotegerin mRNA is increased by interleukin-1 alpha in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells | Q41016610 | ||
| Osteoblast-like cells from human subchondral osteoarthritic bone demonstrate an altered phenotype in vitro: possible role in subchondral bone sclerosis | Q42455211 | ||
| Differential gene expression and regulation of the bone morphogenetic protein antagonists follistatin and gremlin in normal and osteoarthritic human chondrocytes and synovial fibroblasts | Q42466726 | ||
| Osteocalcin synthesis by human osteoblasts from normal and osteoarthritic bone after vitamin D3 stimulation | Q42476279 | ||
| Abnormal regulation of urokinase plasminogen activator by insulin-like growth factor 1 in human osteoarthritic subchondral osteoblasts | Q42478841 | ||
| Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts | Q42507953 | ||
| Differential regulation of Cbfa1/Runx2 and osteocalcin gene expression by vitamin-D3, dexamethasone, and local growth factors in primary human osteoblasts | Q44059999 | ||
| Study of the role of leukotriene B()4 in abnormal function of human subchondral osteoarthritis osteoblasts: effects of cyclooxygenase and/or 5-lipoxygenase inhibition | Q44068955 | ||
| In vitro differentiation of embryonic stem cells into mineralized osteoblasts | Q44296965 | ||
| Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes | Q44394411 | ||
| Glucosamine and chondroitin sulfate: biological response modifiers of chondrocytes under simulated conditions of joint stress | Q44439622 | ||
| Modulation of native chondroitin sulphate structure in tissue development and in disease | Q44706510 | ||
| Effects of 1,25-dihydroxyvitamin D3 on the expressions of osteoprotegerin and receptor activator of NF-kappaB ligand in mouse osteoblasts | Q45066891 | ||
| Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. | Q53768934 | ||
| 1,25-Dihydroxyvitamin D(3) and prostaglandin E(2) act directly on circulating human osteoclast precursors | Q73101643 | ||
| Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study | Q78667350 | ||
| Normal human osteoclasts formed from peripheral blood monocytes express PTH type 1 receptors and are stimulated by PTH in the absence of osteoblasts | Q81424526 | ||
| Subchondral bone sclerosis in osteoarthritis: not just an innocent bystander | Q87030169 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | osteoarthritis | Q62736 |
| osteoblast | Q917177 | ||
| glucosamine | Q32907954 | ||
| P304 | page(s) | R117 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Arthritis Research and Therapy | Q15757229 |
| P1476 | title | Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study | |
| P478 | volume | 9 |
| Q42292745 | A pharmacoproteomic study confirms the synergistic effect of chondroitin sulfate and glucosamine. |
| Q34655436 | Chondroitin and glucosamine in the management of osteoarthritis: an update |
| Q37391095 | Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study |
| Q36059429 | Chondroitin sulfate in the treatment of osteoarthritis: from in vitro studies to clinical recommendations. |
| Q34906145 | Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI |
| Q38838064 | Chondroitin sulphate: a focus on osteoarthritis |
| Q46032045 | Comparison of the ability of chondroitin sulfate derived from bovine, fish and pigs to suppress human osteoclast activity in vitro. |
| Q38371965 | Discrepancies in composition and biological effects of different formulations of chondroitin sulfate. |
| Q30588700 | Disease-modifying osteoarthritis drugs: in vitro and in vivo data on the development of DMOADs under investigation. |
| Q48818751 | Effects of anti-aggregant, anti-inflammatory and anti-coagulant drug consumption on the preparation and therapeutic potential of plasma rich in growth factors (PRGF). |
| Q48172499 | Effects of chrondro-osseous regenerative compound associated with local treatments in the regeneration of bone defects around implants: an in vivo study. |
| Q35861394 | Effects of corticosteroids and their combinations with hyaluronanon on the biochemical properties of porcine cartilage explants |
| Q38758657 | Feline hip dysplasia: A challenge to recognise and treat. |
| Q34396147 | Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens |
| Q37310621 | Immunomodulatory and anti-inflammatory effects of chondroitin sulphate |
| Q38027919 | Impact of inflammation on the osteoarthritic niche: implications for regenerative medicine. |
| Q44118071 | Importance of pharmaceutical composition and evidence from clinical trials and pharmacological studies in determining effectiveness of chondroitin sulphate and other glycosaminoglycans: a critique |
| Q43700545 | Intra-articular delivery of glucosamine for treatment of experimental osteoarthritis created by a medial meniscectomy in a rat model. |
| Q21195259 | Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis? |
| Q38669607 | Levels of serum biomarkers from a two-year multicentre trial are associated with treatment response on knee osteoarthritis cartilage loss as assessed by magnetic resonance imaging: an exploratory study |
| Q39083233 | Medical application of glycosaminoglycans: a review |
| Q33631650 | Pharmacoproteomic study of the effects of chondroitin and glucosamine sulfate on human articular chondrocytes |
| Q36334666 | Protective effects of Tougu Xiaotong capsule on tumor necrosis factor-α-injured UMR-106 cells |
| Q47355810 | Sequential activation of the AKT pathway in human osteoblasts treated with Oscarvit: a bioactive product with positive effect both on skeletal pain and mineralization in osteoblasts |
| Q37596611 | Targeting subchondral bone for treating osteoarthritis: what is the evidence? |
| Q38166991 | The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments? |
| Q33679221 | The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination |
| Q38001412 | The osteoarthritic niche and modulation of skeletal stem cell function for regenerative medicine |
Search more.